HRS-4357

· Jiangsu HengRui Medicine Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HRS-4357, covering 2023-08-23 to 2026-02-04. Get the full timeline:

Most recent: Clinical Trial Update: A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer [Phase 3]

See pricing